134 related articles for article (PubMed ID: 1302767)
1. Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients.
Bruno R; Iliadis MC; Lacarelle B; Cosson V; Mandema JW; Le Roux Y; Montay G; Durand A; Ballereau M; Alasia M
J Pharmacokinet Biopharm; 1992 Dec; 20(6):653-69. PubMed ID: 1302767
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Bayesian estimation to discriminate subpopulations of patients with altered pharmacokinetics using fragmentary data: a pilot study with pefloxacin.
Bruno R; Rosier P; Iliadis A; Le Roux Y; Montay G; Frydman A; Gaillot J
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():338-45. PubMed ID: 1820906
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.
Staatz CE; Tett SE
Eur J Clin Pharmacol; 2002 Dec; 58(9):597-605. PubMed ID: 12483452
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic analysis of meropenem in Japanese adult patients.
Muro T; Sasaki T; Hosaka N; Umeda Y; Takemoto S; Yamamoto H; Kamimura H; Higuchi S; Karube Y
J Clin Pharm Ther; 2011 Apr; 36(2):230-6. PubMed ID: 21366653
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of flucytosine: comparison and validation of three models using STS, NPEM, and NONMEM.
Vermes A; Math t RA; van der Sijs IH; Dankert J; Guchelaar HJ
Ther Drug Monit; 2000 Dec; 22(6):676-87. PubMed ID: 11128235
[TBL] [Abstract][Full Text] [Related]
6. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
7. A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam.
Maitre PO; Bührer M; Thomson D; Stanski DR
J Pharmacokinet Biopharm; 1991 Aug; 19(4):377-84. PubMed ID: 1920085
[TBL] [Abstract][Full Text] [Related]
8. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients.
Saint-Marcoux F; Marquet P; Jacqz-Aigrain E; Bernard N; Thiry P; Le Meur Y; Rousseau A
Clin Pharmacokinet; 2006; 45(9):905-22. PubMed ID: 16928152
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of carbamazepine in Singapore epileptic patients.
Chan E; Lee HS; Hue SS
Br J Clin Pharmacol; 2001 Jun; 51(6):567-76. PubMed ID: 11422016
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation.
Launay-Iliadis MC; Bruno R; Cosson V; Vergniol JC; Oulid-Aissa D; Marty M; Clavel M; Aapro M; Le Bail N; Iliadis A
Cancer Chemother Pharmacol; 1995; 37(1-2):47-54. PubMed ID: 7497596
[TBL] [Abstract][Full Text] [Related]
11. [Estimation of individual pharmacokinetic parameters using maximum a posteriori Bayesian method with D-optimal sampling strategy].
Ding JJ; Jiao Z; Wang Y
Yao Xue Xue Bao; 2011 Dec; 46(12):1493-500. PubMed ID: 22375425
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke.
Jönsson S; Cheng YF; Edenius C; Lees KR; Odergren T; Karlsson MO
Clin Pharmacokinet; 2005; 44(8):863-78. PubMed ID: 16029070
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic parameters of vancomycin in critically ill patients.
Llopis-Salvia P; Jiménez-Torres NV
J Clin Pharm Ther; 2006 Oct; 31(5):447-54. PubMed ID: 16958822
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.
Aumente D; Buelga DS; Lukas JC; Gomez P; Torres A; García MJ
Clin Pharmacokinet; 2006; 45(12):1227-38. PubMed ID: 17112298
[TBL] [Abstract][Full Text] [Related]
16. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic modeling: the importance of informative graphics.
Ette EI; Ludden TM
Pharm Res; 1995 Dec; 12(12):1845-55. PubMed ID: 8786955
[TBL] [Abstract][Full Text] [Related]
18. A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer.
Climente-Martí M; Merino-Sanjuán M; Almenar-Cubells D; Jiménez-Torres NV
J Pharm Sci; 2003 Jun; 92(6):1155-65. PubMed ID: 12761805
[TBL] [Abstract][Full Text] [Related]
19. Influence of biological variables upon pharmacokinetic parameters of intramuscular methotrexate in rheumatoid arthritis.
Debord J; Carpentier N; Sabot C; Bertin P; Marquet P; Treves R; Merle L; Lachâtre G
Int J Clin Pharmacol Ther; 1998 Apr; 36(4):227-30. PubMed ID: 9587050
[TBL] [Abstract][Full Text] [Related]
20. NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias.
Periclou AP; Avramis VI
Cancer Chemother Pharmacol; 1996; 39(1-2):42-50. PubMed ID: 8995498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]